ArticleCerebellum (London, England)2026
An International Survey of Patients with Ataxia: Trends in Patient-Reported Symptoms.
Article in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ataxia disorders have complex symptomology and few treatment options. Limited information is available on symptoms and quality of life with ataxia from the perspective of patients and caregivers. We aimed to assess whether trends in symptoms and quality of life varied by ataxia type and disease stage. We conducted an anonymous, international survey of 680 National Ataxia Foundation Members, including 587 people with ataxia and 93 caregivers. Data was analyzed for the whole group, by ataxia type, and by Functional Disability Stage (FDS). Respondents self-reported the first symptoms experienced, symptoms currently experienced, and the one symptom that currently has the greatest impact on their life. Impaired balance (51%, n = 343) and coordination (24%, n = 161) were the most reported first symptoms noticed by respondents across ataxia types. Impaired balance (92%, n = 627), impaired coordination (80%, n = 546), and fatigue (70%, n = 479) were the most prevalent symptoms across ataxia types and FDS. Impaired balance (65%, n = 443) was the most reported symptom as having the greatest impact on respondents' day-to-day life. While there were commonalities between FDS and ataxia types, some subtype differences emerged amongst self-reported first symptom, symptom prevalence, and symptoms impacting daily living. This study highlights trends in symptomology across ataxia types and disease stages from the perspective of people with ataxia and caregivers. While similarities exist across ataxia types, variation in which symptoms most impact quality of life across disease stages underscores the importance of selecting patient-relevant clinical trial outcome measures and endpoints. These findings can further guide clinicians in prioritizing symptom management and treatment planning, while supporting more meaningful, patient-centered discussions about disease impact.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.